# Ross A. Soo

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/ross-a-soo/

## Facts

| Field | Value |
| --- | --- |
| Citations | 20,008 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 69 |
| i10-index | 222 |
| Last Known Institution | National University Cancer Institute, Singapore |
| OpenAlex ID | https://openalex.org/A5032293215 |
| ORCID iD | 0000-0002-3053-3997 |
| Works | 686 |

## Researcher papers

Showing 12 of 16.

- [Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study](https://scholariq.org/papers/lorlatinib-in-patients-with-alk-positive-non-small-cell-lung-cancer-results-from/)
- [De-novo and acquired resistance to immune checkpoint targeting](https://scholariq.org/papers/de-novo-and-acquired-resistance-to-immune-checkpoint-targeting/)
- [Isolation and retrieval of circulating tumor cells using centrifugal forces](https://scholariq.org/papers/isolation-and-retrieval-of-circulating-tumor-cells-using-centrifugal-forces/)
- [Glycine Decarboxylase Activity Drives Non-Small Cell Lung Cancer Tumor-Initiating Cells and Tumorigenesis](https://scholariq.org/papers/glycine-decarboxylase-activity-drives-non-small-cell-lung-cancer-tumor/)
- [Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial](https://scholariq.org/papers/atezolizumab-in-combination-with-carboplatin-and-nab-paclitaxel-in-advanced/)
- [Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study](https://scholariq.org/papers/durvalumab-as-third-line-or-later-treatment-for-advanced-non-small-cell-lung/)
- [Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer](https://scholariq.org/papers/structural-biochemical-and-clinical-characterization-of-epidermal-growth-factor/)
- [A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer](https://scholariq.org/papers/a-common-bim-deletion-polymorphism-mediates-intrinsic-resistance-and-inferior/)
- [<i>ALK</i> Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/i-alk-i-resistance-mutations-and-efficacy-of-lorlatinib-in-advanced-anaplastic/)
- [Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial](https://scholariq.org/papers/lorlatinib-in-advanced-ros1-positive-non-small-cell-lung-cancer-a-multicentre/)
- [Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus](https://scholariq.org/papers/managing-cancer-patients-during-the-covid-19-pandemic-an-esmo-multidisciplinary/)
- [Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS](https://scholariq.org/papers/pan-asian-adapted-clinical-practice-guidelines-for-the-management-of-patients/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [National University Cancer Institute, Singapore](https://scholariq.org/institutions/national-university-cancer-institute-singapore/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.